Antoxerene and Juvenescence launch FoxBio to develop anti-aging drugs

Antoxerene, a pharmaceutical company dedicated to developing senolytic drugs, has partnered with investment firm Juvenescence to form a joint venture named FoxBio. This new entity will focus on advancing small molecule drugs aimed at combating diseases associated with aging.

FoxBio’s mission is to develop a series of small molecules from Antoxerene that specifically target senescent cells—cells that have stopped dividing and contribute to age-related ailments. Juvenescence supports this venture with a $10 million equity investment, bringing not only capital but also extensive drug development expertise to the table.

Antoxerene, a portfolio company of Ichor Therapeutics, specializes in the discovery of small molecules through the study of protein-protein interactions. These interactions are crucial for the survival of senescent cells which are implicated in the progression of various diseases tied to aging. By targeting these cells, Antoxerene aims to mitigate the deleterious effects they have on the body, potentially reversing or preventing age-associated conditions.

Kelsey Moody, CEO of Antoxerene, expressed enthusiasm about the collaboration, stating, “There has been a lot of interest surrounding the therapeutic applications of senolytic drugs—compounds that clear toxic senescent cells—particularly with respect to age-associated disease. As molecular pathways unique to senescent cells have begun to be identified, we can now develop drugs to target these pathways.” He highlighted the strategic alignment with Juvenescence’s team, noting their experience and visionary leadership as critical to realizing the potential of senolytics.

Dr. Greg Bailey, CEO of Juvenescence, also commented on the synergy between the two companies, saying, “FoxBio plays to both companies’ strengths, which is why we are excited about working with the Antoxerene team. We are fascinated with the Antoxerene platform and its ability to discover intriguing compounds in the area of senescence.”

The establishment of FoxBio is a promising development in the field of longevity and anti-aging research. With Juvenescence’s track record in successful drug development and Antoxerene’s innovative approach to molecular discovery, FoxBio is poised to make significant advancements in the development of therapies that extend human healthspan and combat the diseases of aging.

The collaboration between Antoxerene and Juvenescence through FoxBio represents a significant step forward in the fight against aging. By focusing on senolytic drugs, FoxBio could potentially transform the approach to treating age-related diseases, offering hope for improved quality of life and longevity.